Clinical trials: GLP-1
Healthy Participants
The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA
It is well established that alterations in the portal vein insulin:glucagon ratio play a major role in the dysregulated hepatic glucose metabolism in type 2 diabetes but the molecular mechanism by which glucagon promotes…
- Trial name
- NCT03965130
- Testing
- Glucagon, Control Study
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Yale University
Incretin Effect
Quantification of the Incretin Effect in Healthy Subjects and Patients With Type 2 Diabetes
Patients with T2DM lac a sufficient incretin response after oral glucose intake. It has only been tested using 50g of glucose. We don't know if patients with T2DM are capable of regulating the incretin effect like healthy people…
- Trial name
- NCT00529048
- Testing
- Oral Glucose Tolerance Test, Isoglycemic clamp, Gastric emptying rate
- Where
- Denmark
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Herlev Hospital
Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus
Effect of Gelofusine on GLP1-receptor Imaging
The highly promising and innovative tracer on 111In-DTPA-AHX-Lys40-Exendin 4 has been applied to determine beta cell mass in healthy volunteers and patients with type 1 diabetes.
- Trial name
- GLP1-EX-GELO (NCT02541734)
- Testing
- Gelofusine, 111In-exendin 4 SPECT/CT
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Laxity; Skin
Evaluate the Safety and Efficacy of a Topical Serum (AGE Serum) in Improving Visible Signs of Aging
The primary objective is to evaluate the safety and efficacy of a topical serum (AGE serum) in improving visible signs of aging (e.g., fine lines, wrinkles, sagging, texture, radiance) on the full face and neck.The study will be…
- Trial name
- NCT07216352
- Testing
- AGE Serum
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Goldman, Butterwick, Fitzpatrick and Groff
Alcohol Use Disorder
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)
This clinical trial aims to test the effectiveness and safety of semaglutide, a GLP-1 receptor agonist, in treating moderate to severe alcohol use disorder (AUD) in Veterans.
- Trial name
- CRAVE (NCT07218354)
- Testing
- Semaglutide
- Where
- 19 sites in United States
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Exploratory Behavior
The Role of Endogenous GLP-1 (Glycolipoprotein) in Regulating Glucose Stimulated Brain Activity
Our objective is to investigate neuro-anatomical correlates of the regulation of energy intake by means of functional MRI. Administration of glucose with and without lactisole and exendin as well as fructose is followed by…
- Trial name
- NCT01918566
- Testing
- tap water, Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube, Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole
- Where
- Switzerland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Obesity
Incretin Effect in People With Impaired Fasting Glucose
Regulation of endogenous glucose production (EGP) and insulin secretion are major actions of glucagon-like peptide-1 (GLP-1). Determining whether alterations in GLP-1 may contribute to abnormal EGP and insulin secretion in people…
- Trial name
- 1651 (NCT00795275)
- Testing
- Sitagliptin Phosphate
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type 2
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.
This study will use scintigraphy techniques to measure gastric emptying rate of liquid and solid food at baseline and after administration of GSK716155 or placebo.
- Trial name
- NCT00537719
- Testing
- GSK716155
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes, Type 1 Diabetes
The Effect of GLP-1 on the Inhibition of Glucagon Secretion
Diabetes(both types) are recognized by high levels of glucagon in the circulation. Glucagon is known to increase blood glucose, and might therefore contribute to the respective diseases.
- Trial name
- NCT01507597
- Testing
- Native human Glucagon-like Peptide-1 ( GLP-1(7-36)), NaCl
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type-2 Diabetes, Healthy
Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects
The purpose of this study is to assess the GLP-1 and non-GLP-1 effects of LAF237 on glucagon secretion, using treatment observations of the overall glycemic response.
- Trial name
- NCT00651105
- Testing
- Vildagliptin
- Where
- 2 sites in Germany
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Novartis
Diabetes Mellitus, Type 2, Anesthesia
Investigation of the Evolution of Gastric Emptying by Gastric Ultra Sonography in Patients Treated With GLP-1 Receptor Agonists on a 7 Days Pausing Period.
Glucagon-like-peptide-1 is a hormone released by the gut enteroendocrine cells. Its secretion occurs after each meal to enable production of insulin and inhibits the production of glucagon to lower after meal glycemia.
- Conditions
- Diabetes Mellitus, Type 2, Anesthesia, Pulmonary Aspiration of Gastric Contents
- Trial name
- NCT06388213
- Testing
- Gastric Ultrasonography
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Healthy, Glucagon Resistance
Interplay Between Interleukin-6 and Glucagon in the Regulation of Human Amino Acid and Protein Homeostasis
The goal of this proof-of-concept study is to learn if interleukin-6 changes the effect of glucagon in healthy volunteers. The main question it aims to answer is: Does IL-6 influence how effectively glucagon lowers the…
- Conditions
- Healthy, Glucagon Resistance, Amino Acid Change
- Trial name
- IGLU (NCT06721910)
- Testing
- Tocilizumab
- Where
- Switzerland
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Diabetes Mellitus, Diabetes Mellitus, Type 1
Pharmacokinetics Study of Gamma-aminobutyric Acid
The purpose of this study is to determine upon administering GABA orally to a person how it is absorbed, distributed, as well as the drug's pharmacological effects on the body such as glucose levels, serum C-peptide and/or…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Diseases
- Trial name
- GABA-PK (NCT01917760)
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
End Stage Renal Disease
Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).
A study of the effects of empagliflozin, a SGLT-2 inhibitor, on endogenous glucose production and plasma glucagon levels in patients with end-stage renal disease (ESRD)
- Trial name
- NCT03713190
- Testing
- Empagliflozin
- Where
- Italy
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Pisa
Obesity
Effects of Intravenous Infusions of Gut Hormones on Appetite and Metabolism.
The purpose of this study is to investigate the effects of intravenous infusion of two gastrointestinal hormones, PYY3-36 and GLP-1, alone and in combination, on appetite in healthy obese men.
- Trial name
- INGEAR-1 (NCT00940134)
- Testing
- PYY 3-36, GLP-1, saline infusion
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Insulin Resistance, Deteriorated Glucose Homeostasis
Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose Tolerance
The incretin effect in patients with type two diabetes is reduced. The investigators have previously shown that it is possible to induce a defect in the incretin effect in healthy individuals.
- Conditions
- Insulin Resistance, Deteriorated Glucose Homeostasis, Inactivity
- Trial name
- NCT01173978
- Testing
- Steroid hormone, No intervention
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Glostrup University Hospital, Copenhagen
Type 1 Diabetes
GLP-1 Receptor Targeting in Diabetic and Healthy Individuals
The purpose of the study is to determine whether there are differences in pancreatic uptake of the radiotracer between healthy individuals and patients with type 1 diabetes.
- Trial name
- GLP-1-CPOP (NCT01825148)
- Testing
- radiolabeled Exendin
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Healthy Subjects
Incretin and KATP Channels
This study aims to examine the involvement of KATP channels on the microvascular actions of the incretin GLP-1 and its analogues in healthy individuals and to determine whether the acute oral administration of different KATP…
- Trial name
- NCT01934816
- Testing
- Intradermal injections of GLP-1 and its analogues
- Where
- United Kingdom
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Katarina Kos
End-stage Renal Disease
The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease
Patients with end-stage renal disease (ESRD) have a high prevalence of impaired glucose metabolism. The pathophysiological cause is uncertain, but disturbances in the secretion, elimination and effect of glucagon, insulin and the…
- Trial name
- NCT02237521
- Testing
- Eu- and hyperglycemic clamp, Arginine test
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bo Feldt-Rasmussen
Type 2 Diabetes, Obesity
The Microvascular Function of GLP-1 and Its Analogues
Incretins have become a successful drug target in the repertoire of medications used for the treatment of type 2 diabetes. However little is known about a potential benefit of GLP-1 on the vascular system in humans, independent…
- Trial name
- NCT01677104
- Testing
- GLP-1
- Where
- United Kingdom
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Katarina Kos